Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards

Science Communicator Platform

Share By

Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards Publisher Pubmed

Nabavi SF¹ ; Sahebnasagh A² ; Shahbazi A³ ; Nabavi SM¹ ; Azimi S⁴ ; Kashani MK⁵ ; Habtemariam S⁶ ; Rahmani M⁷ ; Badiee M⁷ ; Hashemi J⁸ ; Saghafi F⁹ ; Amini K¹⁰ ; Azimi M¹¹ ; Rezabakhsh A¹²

Source: Current Medicinal Chemistry Published:2023

Abstract

Given the importance of COVID-19-induced ARDS, recently, researchers have strived to determine underlying mechanisms involved in the inflammatory responses. In this regard, inflammasomes possess a distinct priority for cytokine storm occurrence and, subsequently, ARDS progression in ill patients with SARS-CoV-2 infection. In this minireview, the characteristics of known inflammasome inhibitors and designed research in this field were concretely deciphered. © 2023 Bentham Science Publishers.

Related Docs

View other Related Docs

1. Nlrp3 Inflammasomes Pathway: A Key Target for Metformin, Inflammopharmacology (2025)

2. Nlrp3 Inflammasome Pathway in Atherosclerosis: Focusing on the Therapeutic Potential of Non-Coding Rnas, Pathology Research and Practice (2023)

3. Can Anti-Parasitic Drugs Help Control Covid-19?, Future Virology (2022)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (2)

Mohammad Mehdi Amiri (1)

Other Related Docs

4. Targeting Nlrp3 Inflammasomes: A Trojan Horse Strategy for Intervention in Neurological Disorders, Molecular Neurobiology (2025)

5. Venous Thromboembolism in Viral Diseases: A Comprehensive Literature Review, Health Science Reports (2023)

6. Evidence for the Benefits of Melatonin in Cardiovascular Disease, Frontiers in Cardiovascular Medicine (2022)

7. Nlrp3 Inflammasome: Significance and Potential Therapeutic Targets to Advance Solid Organ Transplantation, Expert Opinion on Therapeutic Targets (2025)

8. Th17 and Treg Cells Function in Sars-Cov2 Patients Compared With Healthy Controls, Journal of Cellular Physiology (2021)

9. Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?, ACS Pharmacology and Translational Science (2021)

10. Pathological Effects of Sars-Cov-2 on Hematological and Immunological Cells: Alterations in Count, Morphology, and Function, Pathology Research and Practice (2022)

11. Infection and Immunity, Clinical Immunology (2022)

12. Sars-Cov-2 Nucleocapsid: Biological Functions and Implication for Disease Diagnosis and Vaccine Design, Reviews in Medical Virology (2023)

13. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm, Journal of Clinical Immunology (2020)

14. The Role of Lovastatin in the Attenuation of Covid-19, International Immunopharmacology (2021)

15. Nanostructures for Prevention, Diagnosis, and Treatment of Viral Respiratory Infections: From Influenza Virus to Sars-Cov-2 Variants, Journal of Nanobiotechnology (2023)

16. Classification of the Present Pharmaceutical Agents Based on the Possible Effective Mechanism on the Covid-19 Infection, DARU# Journal of Pharmaceutical Sciences (2020)

17. Cytokine Profiles Dynamics in Covid-19 Patients: A Longitudinal Analysis of Disease Severity and Outcomes, Scientific Reports (2025)

18. Association Between Serum Inflammatory Parameters and the Disease Severity in Covid-19 Patients, Journal of Clinical Laboratory Analysis (2022)

19. Repurposing Metformin for Covid-19 Complications in Patients With Type 2 Diabetes and Insulin Resistance, Immunopharmacology and Immunotoxicology (2021)

20. Caspase-1 Inhibition Prevents Glial Inflammasome Activation and Pyroptosis in Models of Multiple Sclerosis, Proceedings of the National Academy of Sciences of the United States of America (2018)

Style	Citing Format
MLA	Nabavi SF, et al.. "Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards." Current Medicinal Chemistry, vol. 30, no. 12, 2023, pp. 1406-1419.
APA	Nabavi SF, Sahebnasagh A, Shahbazi A, Nabavi SM, Azimi S, Kashani MK, Habtemariam S, Rahmani M, Badiee M, Hashemi J, Saghafi F, Amini K, Azimi M, Rezabakhsh A (2023). Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards. Current Medicinal Chemistry, 30(12), 1406-1419.
Chicago	Nabavi SF, Sahebnasagh A, Shahbazi A, Nabavi SM, Azimi S, Kashani MK, Habtemariam S, et al.. "Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards." Current Medicinal Chemistry 30, no. 12 (2023): 1406-1419.
Harvard	Nabavi SF et al. (2023) 'Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards', Current Medicinal Chemistry, 30(12), pp. 1406-1419.
Vancouver	Nabavi SF, Sahebnasagh A, Shahbazi A, Nabavi SM, Azimi S, Kashani MK, et al.. Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards. Current Medicinal Chemistry. 2023;30(12):1406-1419.
BibTex	@article{ author = {Nabavi SF and Sahebnasagh A and Shahbazi A and Nabavi SM and Azimi S and Kashani MK and Habtemariam S and Rahmani M and Badiee M and Hashemi J and Saghafi F and Amini K and Azimi M and Rezabakhsh A}, title = {Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards}, journal = {Current Medicinal Chemistry}, volume = {30}, number = {12}, pages = {1406-1419}, year = {2023} }
RIS	TY - JOUR AU - Nabavi SF AU - Sahebnasagh A AU - Shahbazi A AU - Nabavi SM AU - Azimi S AU - Kashani MK AU - Habtemariam S AU - Rahmani M AU - Badiee M AU - Hashemi J AU - Saghafi F AU - Amini K AU - Azimi M AU - Rezabakhsh A TI - Putative Therapeutic Impact of Inflammasome Inhibitors Against Covid-19-Induced Ards JO - Current Medicinal Chemistry VL - 30 IS - 12 SP - 1406 EP - 1419 PY - 2023 ER -

Science Communicator Platform

Authors

Abstract